Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
29 Results for "
FGF receptor
" in MedChemExpress (MCE) Product Catalog:
Products (29)
29 Results for "FGF receptor" in MCE Product Catalog:
3
3 Cited Publications
SU16f is a potent and selective PDGFRβ inhibitor with IC50s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, VEGF-R2, FGF-R1, respectively . Neutralization of PDGFRβ receptor by SU16f blocks the promoting role of GC-MSCs (gastric cancer-derived mesenchymal stem cells) conditioned medium in gastric cancer cell proliferation and migration .
2
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P72434
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TNFRSF12A; Tumor Necrosis Factor receptor Superfamily Member 12A; TNF receptor Superfamily Member 12A; FGF-Inducible 14; TweakR; Tweak-receptor; FN14; Tumor Necrosis Factor receptor Superfamily, Member 12A; CD266; Type I Transmembrane Protein Fn14; Fibrob
Cat. No.: HY-P99010
CAS No.: 1952272-74-0
Synonyms: AMG-552; FPA-144
Target:
Research Areas:
PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively. PD-161570 inhibits PDGF-stimulated autophosphorylation and FGF-1 receptor phosphorylation with IC50s of 450 nM and 622 nM, respectively . PD-161570 is also a bone morphogenetic proteins (BMPs) and TGF-β signaling inhibitor .
Research Areas:
PRX-08066 is a selective and orally active 5-hydroxytryptamine receptor 2B (5-HT2BR) antagonist with a Ki of 3.4 nM. PRX-08066 inhibits the MAPK pathway, 5-HT release and fibrotic factor (TGFβ1, CTGF and FGF2) expression. PRX-08066 inhibits the proliferation of KRJ-I cells and induces apoptosis (caspase-3 activation). PRX-08066 inhibits pulmonary vascular remodeling. PRX-08066 can be used of pulmonary Arterial Hypertension (PAH) and neuroendocrine tumor (NET) .
Research Areas:
PD 174265 is a highly selective, reversible EGFR/ErbB2 tyrosine kinase inhibitor (IC50=0.45 nM) and cell differentiation inducer. By blocking receptor autophosphorylation and the downstream ERK signaling pathway (with an IC50 of 0.45 μM for full-length ERK), PD 174265 effectively inhibits tumor growth and exhibits antitumor activity without obvious toxicity in in vivo models. PD 174265 drives oligodendrocyte precursor cells to switch from a proliferative state to a differentiated state, significantly upregulates the expression of myelin proteins such as CNP, PLP and MBP, and induces neurite branching. PD 174265 shows no inhibitory effect on other kinases including insulin, PDGF and basic FGF receptors, and serves as a crucial tool molecule for investigating the treatment of human epidermoid carcinoma and the mechanism of myelin repair in multiple sclerosis .
Cat. No.: HY-172443
CAS No.: 169799-44-4
Target:
Research Areas:
Keratin sulfate is a heparin-related proteoglycan that interacts with the receptor or alters its stability and function. Keratin sulfate does not enhance the mitogenic effect of FGF-2 .
Cat. No.: HY-118792
CAS No.: 352346-46-4
Target:
Research Areas:
AHR activator 1 is an aryl hydrocarbon receptor activator with activity regulating fibroblast growth factor-2 (FGF2)-induced branching morphogenesis. AHR activator 1 prevents the formation of cellular branches by inhibiting AHR signaling. AHR activator 1 also associates with adhesion of dissociated linkers, suggesting the importance of dissociated linkers in the inhibition of branching by AHR agonists. Studies of AHR activator 1 reveal its functional role in mammary gland morphogenesis and play a role in inhibiting FGF-induced invasion .
Cat. No.: HY-112353
CAS No.: 949164-80-1
Target:
Research Areas:
NP603 is a potent inhibitor of FGF receptor 1, exhibiting remarkable activity against endothelial proliferation in HUVEC cells stimulated by rhFGF-2, with a minimum effective dose of 0.4 microM.
Cat. No.: HY-161840
Antitumor agent-176 (Compound 22), an antitumor agent, can effectively bind to FGF2 and inhibit the activation of fibroblast growth factor receptor (FGFR) in multiple myeloma (MM) cells, exhibiting significant antitumor activity both in vivo and in vitro against MM .
Cat. No.: HY-165603
CAS No.: 3006860-57-4
Research Areas:
Si5-N14 is a key component of siloxane-incorporated lipid nanoparticles (SiLNP), possessing pro-vascular repair and anti-tumor activities. In the transgenic GFP mouse model, Si5-N14 can mediate CRISPR-Cas9 editing. In the Lewis lung carcinoma (LLC) tumor-bearing mouse model, Si5-N14 can knock out the expression of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) to exert an anti-tumor effect. In a mouse model of lung injury induced by viral infection, the delivery of Fibroblast Growth Factor-2 (FGF-2) mRNA via Si5-N14 can promote vascular repair, increase blood oxygen levels, and improve lung function. Si5-N14 shows promise for research in the fields of oncology, pneumonia, and cardiovascular diseases .
Cat. No.: HY-15472A
CAS No.: 866206-55-5
Research Areas:
PRX-08066 maleate is a selective and orally active 5-hydroxytryptamine receptor 2B (5-HT2BR) antagonist with a Ki of 3.4 nM. PRX-08066 maleate inhibits the MAPK pathway, 5-HT release and fibrotic factor (TGFβ1, CTGF and FGF2) expression. PRX-08066 maleate inhibits the proliferation of KRJ-I cells and induces apoptosis (caspase-3 activation). PRX-08066 maleate inhibits pulmonary vascular remodeling. PRX-08066 maleate can be used of pulmonary Arterial Hypertension (PAH) and neuroendocrine tumor (NET) .
Cat. No.: HY-10335
CAS No.: 651744-16-0
Research Areas:
BMS-645737 is an orally active, selective FGF receptor-1 and VEGF receptor-2 inhibitor. BMS-645737 selectively and competitively inhibits both VEGFR-2 and FGFR-1 tyrosine kinases. BMS-645737 has anti-angiogenic activity. BMS-645737 induces lesions in the incisor teeth .
Cat. No.: HY-P76343
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: FGFRL1; FGF receptor-Like Protein 1; Fibroblast Growth Factor receptor Like 1; FGFR-Like Protein; FGFR5; FGFR-5; Fibroblast Growth Factor receptor 5; FHFR; Fibroblast Growth Factor receptor-Like 1; FGFRL1 Protein; FGF Homologous Factor receptor
Cat. No.: HY-P72643
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: FGFRL1; FGF receptor-Like Protein 1; Fibroblast Growth Factor receptor Like 1; FGFR-Like Protein; FGFR5; FGFR-5; Fibroblast Growth Factor receptor 5; FHFR; Fibroblast Growth Factor receptor-Like 1; FGFRL1 Protein; FGF Homologous Factor receptor
Cat. No.: HY-10321G
CAS No.: 219580-11-7
Cat. No.: HY-P71909
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TNFRSF12A; Tumor Necrosis Factor receptor Superfamily Member 12A; TNF receptor Superfamily Member 12A; FGF-Inducible 14; TweakR; Tweak-receptor; FN14; Tumor Necrosis Factor receptor Superfamily, Member 12A; CD266; Type I Transmembrane Protein Fn14; Fibrob
Cat. No.: HY-P72435
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TNFRSF12A; Tumor Necrosis Factor receptor Superfamily Member 12A; TNF receptor Superfamily Member 12A; FGF-Inducible 14; TweakR; Tweak-receptor; FN14; Tumor Necrosis Factor receptor Superfamily, Member 12A; CD266; Type I Transmembrane Protein Fn14; Fibrob
Cat. No.: HY-P11880
Target:
Research Areas:
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
